Coughlin Timothy — SEC Form 4 filings
SEC reporting owner CIK 1376043. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-16.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-05-10 to 2026-06-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 50,000 shares, $87,500 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 31,250 shares, $1,272,691 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: sale of 18,000 shares @ $35.03 ($630,601) in Travere Therapeutics, Inc., filed 2025-11-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Director | 6 | — | 3 legs · 31,250 sh · $1,272,691 | 12 |
| aTYR PHARMA INC (ATYR) | Director | 4 | 1 leg · 50,000 sh · $87,500 | — | 3 |
| ADC Therapeutics SA (ADCT) | Director | 2 | — | — | 4 |
| Vir Biotechnology, Inc. (VIR) | Director | 1 | — | — | 4 |
| FATE THERAPEUTICS INC (FATE) | Director | 1 | — | — | 1 |
Form 4 filings — Coughlin Timothy
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $26.52 · Sale (S): 10,000 @ $50.07 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 8,000 @ $0 · Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | ADC Therapeutics SA (ADCT) | Grant/award (A): 45,000 @ $0 · Tax withholding (F): 12,600 @ $3.08 | EDGAR |
| 2026-05-21 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 3,250 @ $43.49 | EDGAR |
| 2026-05-13 | 4 | aTYR PHARMA INC (ATYR) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-11-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 8,000 @ $16.33 · Option exercise (M): 10,000 @ $17.44 · Sale (S): 18,000 @ $35.03 · Option exercise (M): 8,000 (derivative) @ $0 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | ADC Therapeutics SA (ADCT) | Grant/award (A): 40,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | aTYR PHARMA INC (ATYR) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | aTYR PHARMA INC (LIFE) | Purchase (P): 50,000 @ $1.75 | EDGAR |
| 2024-05-23 | 4 | aTYR PHARMA INC (LIFE) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1376043 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →